Kwality Pharmaceuticals

Kwality Pharmaceuticals

902.00
-18.10
(-1.97%)
Market Cap
954.70 Cr
EPS
38.36
PE Ratio
21.61
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,235.00
52 Week Low
596.05
PB Ratio
3.56
Debt to Equity
0.43
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Kwality Pharmaceutical Ltd has received product registration for Bleomycin 15 IU per vial in Mexico, expanding its oncology product portfolio in regulated markets. Bleomycin is an anti-cancer medicine used to treat Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company projects a business potential of around 1 million USD in the first year, with supplies expected to commence before the end of Q2FY26. This approval strengthens the company's expansion into highly regulated markets and reinforces its commitment to delivering quality oncology products globally.
neutral
Kwality Pharmaceuticals' Board of Directors approved several key decisions for their 42nd Annual General Meeting scheduled for September 9, 2025. The Board approved re-appointments of multiple directors for five-year terms from January 16, 2026 to January 15, 2031, including Managing Director Ramesh Arora, Whole Time Directors Ajay Kumar Arora, Anju Arora, and Geeta Arora, and Independent Director Kartik Kapur for his second term. The Board also approved regularization of Vinod Kumar Sharma as Additional Independent Director and appointed M/s Rishi Mittal & Associates as Secretarial Auditors for five years. E-voting will be available from September 6-8, 2025, with book closure from September 2-9, 2025. All director re-appointments and auditor appointment are subject to shareholder approval at the AGM.
positive
Kwality Pharmaceuticals Limited reported strong quarterly results with consolidated revenue rising 39.8% year-on-year from ₹80 crore to ₹111.8 crore. EBITDA grew 39% to ₹24.6 crore while maintaining stable margins at around 22%. Net profit increased 43% from ₹8.3 crore to ₹11.9 crore. The company completed a regulatory audit in Zimbabwe and received multiple new product registrations during the quarter. Key upcoming milestones include an EU-GMP audit scheduled for October and a WHO-GMP inspection of their biologics facility later this year. The company is targeting ₹500 crore revenue for FY26 and continues expanding its international presence across over 70 countries with a portfolio exceeding 3,000 formulations.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,636.20
#1 3,82,526.00
34.22
#1 54,729.00
9.71
#1 10,980
-19.84
43.29
5,710.00
1,51,038.30
65.74
9,712.00
18.67
2,191
26.74
28.97
3,567.10
1,21,948.70
59.71
11,539.40
6.99
1,911
19.91
51.91
1,513.00
1,21,429.70
22.68
28,409.50
7.12
5,291
9.88
39.80
1,244.70
1,02,131.70
#1 18.31
33,741.20
16.73
5,725
1.26
34.86
2,439.60
1,00,535.60
53.25
12,744.20
#1 20.90
2,007
-18.14
34.79
991.15
98,802.10
21.41
23,511.00
18.55
4,615
2.60
40.31
1,981.30
87,299.50
24.47
22,909.50
13.74
3,306
#1 51.64
38.96
5,459.50
64,864.00
28.71
13,458.30
3.70
2,216
21.39
52.88
1,086.00
62,953.10
18.78
32,345.60
9.43
3,484
-10.24
49.39
Forecast
Actual
Growth Rate
Revenue Growth
20.42 %
Net Income Growth
68.64 %
Cash Flow Change
22.66 %
ROE
42.98 %
ROCE
34.64 %
EBITDA Margin (Avg.)
0.32 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
121
184
89
66
71
57
57
70
68
70
79
93
80
90
85
117
112
Expenses
73
100
64
48
52
40
41
74
54
54
61
78
63
70
67
90
87
EBITDA
49
84
25
18
18
17
16
-4
14
16
17
14
18
20
18
27
25
Operating Profit %
40 %
45 %
28 %
25 %
26 %
28 %
27 %
-7 %
20 %
22 %
21 %
15 %
22 %
22 %
21 %
22 %
22 %
Depreciation
2
3
3
3
3
4
4
4
5
5
5
5
4
5
5
5
5
Interest
1
1
1
1
1
1
2
2
2
2
3
3
3
3
2
3
3
Profit Before Tax
46
80
22
14
14
12
10
-10
7
8
10
6
11
13
11
19
17
Tax
11
21
6
4
4
2
3
-2
2
2
2
2
3
4
3
5
5
Net Profit
34
60
16
11
11
9
7
-7
5
6
8
4
8
9
9
15
12
EPS in ₹
32.96
57.33
15.20
9.97
9.99
8.82
6.82
-7.23
5.10
5.99
7.39
4.08
8.04
8.15
8.21
13.95
11.49

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
37
51
71
96
105
133
166
341
354
394
447
Fixed Assets
13
13
17
20
29
43
57
92
121
139
146
Current Assets
25
38
53
75
75
89
106
228
207
243
284
Capital Work in Progress
0
0
0
0
0
0
3
12
14
0
0
Investments
1
2
3
5
4
3
4
0
0
0
0
Other Assets
24
37
51
71
72
87
102
237
219
255
302
Total Liabilities
37
51
71
96
105
133
166
341
354
394
447
Current Liabilities
17
27
42
62
61
68
78
140
126
152
170
Non Current Liabilities
1
3
4
6
8
20
28
21
29
20
15
Total Equity
19
21
25
29
36
45
60
180
199
223
262
Reserve & Surplus
15
17
20
19
27
36
51
171
190
214
254
Share Capital
4
5
5
10
10
10
10
10
10
10
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
0
2
-1
-0
0
4
3
-6
-1
10
Investing Activities
-1
-3
-7
-6
-12
-18
-23
-63
-48
-26
-29
Operating Activities
1
-3
4
-1
14
6
27
61
41
43
53
Financing Activities
1
6
5
5
-2
12
1
6
1
-17
-14

Share Holding

% Holding
Mar 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
54.13 %
54.24 %
54.24 %
54.43 %
54.45 %
54.45 %
54.45 %
54.74 %
54.74 %
54.77 %
54.77 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.02 %
0.03 %
0.32 %
0.33 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
23.18 %
25.38 %
25.91 %
26.29 %
26.54 %
26.25 %
25.92 %
26.27 %
29.29 %
31.64 %
32.95 %
31.70 %
31.78 %
32.78 %
33.25 %
33.39 %
33.32 %
Others
22.69 %
20.38 %
19.84 %
19.28 %
19.01 %
19.30 %
19.63 %
18.99 %
15.96 %
13.58 %
12.27 %
13.47 %
13.40 %
12.38 %
11.90 %
11.47 %
11.52 %
No of Share Holders
148
168
379
581
1,049
4,198
5,376
6,211
6,943
6,291
5,786
5,695
5,273
7,487
8,947
9,420
10,115

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 1.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
12 Oct 2017 BONUS Bonus
1:1
11 Oct 2017 0.00 0.00
24 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2024 783.50 808.10
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 818.30 812.35
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 892.20 870.20
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2025 719.45 809.00
11 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Aug 2025 1,124.45 1,132.65
09 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Sept 2025 1,069.05 946.35

Announcements

Closure of Trading Window4 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Regularization And Reappointment Of Directors At AGMSep 10, 2025
Appointment Of Secretarial Auditors Of The CompanySep 09, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution.Aug 18, 2025
Notice Of 42Nd AGM Of The Company Scheduled To Be Held On 09Th September 2025Aug 16, 2025
Reg. 34 (1) Annual Report.Aug 16, 2025
Intimation Of Book ClosureAug 16, 2025
42Nd Annual General Meeting (AGM) Of The Shareholders Of The Company Will Be Held On Tuesday The 09Th September 2025 At 12:00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM)Aug 16, 2025
Board Meeting Outcome for Board Meeting Outcome For Intimation Of AGMAug 16, 2025
Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Board Meeting Outcome for Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On 30Th June 2025.Aug 04, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorJul 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 26, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
Board Meeting Outcome for Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
Conclusion Of Regulatory Audit For ZimbabweMay 07, 2025
Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March 2025May 06, 2025
Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November 2018- Fund Raising By Issuance Of Debt Securities By Large CorporateApr 30, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Closure of Trading WindowMar 26, 2025
Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In MexicoFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Integrated Filing (Financial)Jan 31, 2025
UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).Jan 21, 2025
Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024 Along With Limited Review ReportJan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2025
Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoietin (10000 IU/Ml)Jan 02, 2025
Intimation Under Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('SEBI Listing Regulations') - Schedule Of Analyst/ Institutional Investor MeetingNov 27, 2024
Kwality Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-AsparaginaseNov 26, 2024
Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From GreeceNov 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2024
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.Oct 22, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Closure of Trading WindowSep 29, 2024
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 26, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 26, 2024

Technical Indicators

RSI(14)
Neutral
37.06
ATR(14)
Volatile
38.45
STOCH(9,6)
Neutral
26.04
STOCH RSI(14)
Neutral
35.29
MACD(12,26)
Bearish
-1.76
ADX(14)
Strong Trend
44.85
UO(9)
Bearish
43.83
ROC(12)
Downtrend And Accelerating
-6.62
WillR(14)
Oversold
-82.87